1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis grant supports multi-institutional teams developing novel therapeutic agents for adult glioblastoma (GBM), with particular emphasis on therapies capable of crossing the blood-brain barrier and advancing rapidly into early clinical testing.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Multi-institutional teams, investigators based in the United States and Canada are eligible for 2027 awards. Confirm the full requirements in the official notice before applying.
The current listing shows approximately $4.4 million in FY 2027 to support 3–4 awards. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NCI Glioblastoma Therapeutics Network (GTN) U19 Grant are due September 25, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NCI Glioblastoma Therapeutics Network (GTN) U19 Grant is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read article